organization · Reporting owner
En Fidecomiso de Mi Vida 11/23/2010 Trust
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC.ADIL · Entity 7742 | 10% owner | July 31, 2018 | August 02, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADIAL PHARMACEUTICALS, INC.
Report date July 31, 2018 · Filed August 02, 2018
Jointly reported with Johnson Bankole A.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 255,768 |
Reported balance
After 2018-07-31 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-07-31 · Conversion · Acquired 153,114 · Balance 255,768 F1: The 153,114 shares of common stock and a warrant to purchase 153,114 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $52,000 together with interest accrued thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. |
| Common StockSEC Table I · non-derivative | Direct | 273,368 |
Reported balance
After 2018-07-31 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-07-31 · Other · Acquired 17,600 · Balance 273,368 F2: The 17,600 shares were received upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. |
| Common StockSEC Table I · non-derivative | Direct | 1,400 |
Reported balance
After 2018-07-31 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-07-31 · Purchase · Acquired 1,400 · Balance 1,400 F3: On July 31, 2018, Dr. Johnson purchased 1,400 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. |
| Common StockSEC Table I · non-derivative | IndirectMedico-Trans Company, LLC | 313,750 |
Reported balance
After 2018-07-31 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2018-07-31 · Grant · Acquired 40,382 · Balance 313,750 F4: The 40,382 shares were received upon consummation of the initial public offering in accordance with a Services Agreement with Medico-Trans Company, LLC. F5: Medico-Trans Company, LLC is controlled by Bankole Johnson. |
| Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.44 | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2018-07-31 · Conversion · Disposed 153,114 · Balance 0 F1: The 153,114 shares of common stock and a warrant to purchase 153,114 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $52,000 together with interest accrued thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. |
| Warrant to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $6.25 · Expires 2023-07-31 | Direct | 17,600 |
Reported balance
After 2018-07-31 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2018-07-31 · Other · Acquired 17,600 · Balance 17,600 F8: A warrant to purchase 17,600 shares of common stock was issued upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. |
| Warrant to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $6.25 | Direct | 170,714 |
Reported balance
After 2018-07-31 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2018-07-31 · Conversion · Acquired 153,114 · Balance 170,714 F1: The 153,114 shares of common stock and a warrant to purchase 153,114 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $52,000 together with interest accrued thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. |
| Warrant to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $6.25 · Expires 2023-07-31 | Direct | 169,314 |
Reported balance
After 2018-07-31 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2018-07-31 · Purchase · Acquired 1,400 · Balance 169,314 F3: On July 31, 2018, Dr. Johnson purchased 1,400 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. |
| Warrant to purchase unitsSEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2023-07-31 | Direct | 17,600 |
Reported balance
After 2018-07-31 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2018-07-31 · Other · Acquired 17,600 · Balance 17,600 F9: The warrant to purchase 17,600 units was received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 35,200 shares. |
| Common StockSEC Table I · non-derivative | IndirectEn Fideicomiso De Mi Vida 11/23/2010 (Trust) | 850,896 |
Reported balance
Holding disclosure · report date 2018-07-31 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 850,896 F6: Dr. Johnson is the trustee of each of these trusts. |
| Common StockSEC Table I · non-derivative | IndirectEn Fidecomiso de Todos Mis Suenos Grantor Retained Annuity Trust dated June 27, 2017 | 93,000 |
Reported balance
Holding disclosure · report date 2018-07-31 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 93,000 F6: Dr. Johnson is the trustee of each of these trusts. |
| Common StockSEC Table I · non-derivative | IndirectEn Fideicomiso De Mis Suenos 11/23/2010 (Trust) | 22,320 |
Reported balance
Holding disclosure · report date 2018-07-31 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 22,320 F6: Dr. Johnson is the trustee of each of these trusts. |
| Common StockSEC Table I · non-derivative | IndirectDe Mi Amor 11/23/2010 (Trust) | 7,440 |
Reported balance
Holding disclosure · report date 2018-07-31 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 7,440 F6: Dr. Johnson is the trustee of each of these trusts. |
| Common StockSEC Table I · non-derivative | IndirectEfunbowale Johnson | 4,650 |
Reported balance
Holding disclosure · report date 2018-07-31 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 4,650 F7: Dr. Johnson has a voting proxy on this person's behalf that entitles him to vote these shares. |
| Common StockSEC Table I · non-derivative | IndirectAde Johnson | 1,395 |
Reported balance
Holding disclosure · report date 2018-07-31 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 1,395 F7: Dr. Johnson has a voting proxy on this person's behalf that entitles him to vote these shares. |
| Common StockSEC Table I · non-derivative | IndirectLola Johnson | 1,395 |
Reported balance
Holding disclosure · report date 2018-07-31 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 1,395 F7: Dr. Johnson has a voting proxy on this person's behalf that entitles him to vote these shares. |
| Common StockSEC Table I · non-derivative | IndirectLina Tiouririne | 930 |
Reported balance
Holding disclosure · report date 2018-07-31 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 930 F7: Dr. Johnson has a voting proxy on this person's behalf that entitles him to vote these shares. |
| Common StockSEC Table I · non-derivative | IndirectAida Tiouririne | 930 |
Reported balance
Holding disclosure · report date 2018-07-31 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 930 F7: Dr. Johnson has a voting proxy on this person's behalf that entitles him to vote these shares. |
Filing footnotes · ownership attribution and instrument terms
F1: The 153,114 shares of common stock and a warrant to purchase 153,114 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $52,000 together with interest accrued thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018.
F2: The 17,600 shares were received upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.
F3: On July 31, 2018, Dr. Johnson purchased 1,400 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering.
F4: The 40,382 shares were received upon consummation of the initial public offering in accordance with a Services Agreement with Medico-Trans Company, LLC.
F5: Medico-Trans Company, LLC is controlled by Bankole Johnson.
F6: Dr. Johnson is the trustee of each of these trusts.
F7: Dr. Johnson has a voting proxy on this person's behalf that entitles him to vote these shares.
F8: A warrant to purchase 17,600 shares of common stock was issued upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.
F9: The warrant to purchase 17,600 units was received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 35,200 shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2018 Filed Aug 2, 2018 16:08 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseWarrant to purchase common stock · Derivative | 1,400 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-010087 · ownership.xml · derivative · entry 18 Johnson Bankole A. · CIK 0001718158 · Director · 10% owner En Fidecomiso de Mi Vida 11/23/2010 Trust · CIK 0001719033 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,314 Underlying: Common Stock · 1,400 shares Expires 2023-07-31 F3 · shares: On July 31, 2018, Dr. Johnson purchased 1,400 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. F3 · price: On July 31, 2018, Dr. Johnson purchased 1,400 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:08 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase units · Derivative | 17,600 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001213900-18-010087 · ownership.xml · derivative · entry 17 Johnson Bankole A. · CIK 0001718158 · Director · 10% owner En Fidecomiso de Mi Vida 11/23/2010 Trust · CIK 0001719033 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,600 Underlying: Units · 35,200 shares Expires 2023-07-31 F9 · price: The warrant to purchase 17,600 units was received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 35,200 shares. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:08 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | ConversionWarrant to purchase common stock · Derivative | 153,114 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-010087 · ownership.xml · derivative · entry 16 Johnson Bankole A. · CIK 0001718158 · Director · 10% owner En Fidecomiso de Mi Vida 11/23/2010 Trust · CIK 0001719033 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,714 Underlying: Common Stock · 153,114 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The 153,114 shares of common stock and a warrant to purchase 153,114 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $52,000 together with interest accrued thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. F1 · derivative.exercise_date: The 153,114 shares of common stock and a warrant to purchase 153,114 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $52,000 together with interest accrued thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. F1 · derivative.expiration_date: The 153,114 shares of common stock and a warrant to purchase 153,114 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $52,000 together with interest accrued thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:08 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase common stock · Derivative | 17,600 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-010087 · ownership.xml · derivative · entry 15 Johnson Bankole A. · CIK 0001718158 · Director · 10% owner En Fidecomiso de Mi Vida 11/23/2010 Trust · CIK 0001719033 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2023-07-31 F8 · price: A warrant to purchase 17,600 shares of common stock was issued upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:08 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | ConversionConvertible Note · Derivative | 153,114 | $0.44 Strike: $0.44 | $67,370.16 |
DisclosureSEC source: 0001213900-18-010087 · ownership.xml · derivative · entry 14 Johnson Bankole A. · CIK 0001718158 · Director · 10% owner En Fidecomiso de Mi Vida 11/23/2010 Trust · CIK 0001719033 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 153,114 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The 153,114 shares of common stock and a warrant to purchase 153,114 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $52,000 together with interest accrued thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. F1 · derivative.expiration_date: The 153,114 shares of common stock and a warrant to purchase 153,114 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $52,000 together with interest accrued thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:08 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantCommon Stock | 40,382 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-010087 · ownership.xml · nonDerivative · entry 4 Johnson Bankole A. · CIK 0001718158 · Director · 10% owner En Fidecomiso de Mi Vida 11/23/2010 Trust · CIK 0001719033 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Medico-Trans Company, LLC Disclosed balance after: 313,750 F4 · shares: The 40,382 shares were received upon consummation of the initial public offering in accordance with a Services Agreement with Medico-Trans Company, LLC. F4 · price: The 40,382 shares were received upon consummation of the initial public offering in accordance with a Services Agreement with Medico-Trans Company, LLC. F5 · ownership.nature: Medico-Trans Company, LLC is controlled by Bankole Johnson. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:08 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 1,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-010087 · ownership.xml · nonDerivative · entry 3 Johnson Bankole A. · CIK 0001718158 · Director · 10% owner En Fidecomiso de Mi Vida 11/23/2010 Trust · CIK 0001719033 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 F3 · shares: On July 31, 2018, Dr. Johnson purchased 1,400 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. F3 · price: On July 31, 2018, Dr. Johnson purchased 1,400 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:08 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherCommon Stock | 17,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-010087 · ownership.xml · nonDerivative · entry 2 Johnson Bankole A. · CIK 0001718158 · Director · 10% owner En Fidecomiso de Mi Vida 11/23/2010 Trust · CIK 0001719033 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,368 F2 · shares: The 17,600 shares were received upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F2 · price: The 17,600 shares were received upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:08 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | ConversionCommon Stock | 153,114 | $0.44 | $67,370.16 |
DisclosureSEC source: 0001213900-18-010087 · ownership.xml · nonDerivative · entry 1 Johnson Bankole A. · CIK 0001718158 · Director · 10% owner En Fidecomiso de Mi Vida 11/23/2010 Trust · CIK 0001719033 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The 153,114 shares of common stock and a warrant to purchase 153,114 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $52,000 together with interest accrued thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.